These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 21896911

  • 1. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E, Cotter A, Purswani M, PACTG 394 Study Team.
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA, Srinivasan P, Smith TJ, Butkyavichene I, Lopez G, Brooks AA, Martin A, Dinh CT, Smith JM, Baum MM.
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [Abstract] [Full Text] [Related]

  • 3. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
    Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsäcker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Moltó J, Burger DM, PANNA network.
    AIDS; 2013 Mar 13; 27(5):739-48. PubMed ID: 23169329
    [Abstract] [Full Text] [Related]

  • 4. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
    Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N.
    Antimicrob Agents Chemother; 2008 Sep 13; 52(9):3144-60. PubMed ID: 18573931
    [Abstract] [Full Text] [Related]

  • 5. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE, Smolders EJ, Jourdain G, Burger DM, Colbers AP, Cressey TR, PANNA Network and iTAP Study GroupDepartment of Pharmacy, Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands..
    J Clin Pharmacol; 2021 Mar 13; 61(3):388-393. PubMed ID: 32960984
    [Abstract] [Full Text] [Related]

  • 6. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH, Ellis GM, Chintu N, Cantrell RA, Sinkala M, Aldrovandi GM, Warrier R, Mbewe F, Nakamura K, Stringer EM, Frenkel LM, Stringer JS.
    AIDS Res Hum Retroviruses; 2009 Nov 13; 25(11):1099-106. PubMed ID: 19886836
    [Abstract] [Full Text] [Related]

  • 7. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
    Hirt D, Ekouévi DK, Pruvost A, Urien S, Arrivé E, Blanche S, Avit D, Amani-Bosse C, Nyati M, Legote S, Ek ML, Say L, McIntyre J, Dabis F, Tréluyer JM.
    Antimicrob Agents Chemother; 2011 Jun 13; 55(6):2961-7. PubMed ID: 21464249
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.
    HIV Clin Trials; 2014 Jun 13; 15(2):51-6. PubMed ID: 24710918
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, Sinkala M, Smith PJ, Stringer EM, Stringer JS.
    J Acquir Immune Defic Syndr; 2008 Jun 01; 48(2):220-3. PubMed ID: 18520682
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2008 Jun 01; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 17. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF, AI266073 Study Group.
    AIDS Patient Care STDS; 2010 Feb 01; 24(2):87-96. PubMed ID: 20156091
    [Abstract] [Full Text] [Related]

  • 18. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A, AI266073 Study Group.
    J Acquir Immune Defic Syndr; 2009 Jun 01; 51(2):163-74. PubMed ID: 19357529
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
    Hirt D, Urien S, Rey E, Arrivé E, Ekouévi DK, Coffié P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Tréluyer JM.
    Antimicrob Agents Chemother; 2009 Mar 01; 53(3):1067-73. PubMed ID: 19104016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.